OREANDA-NEWS. The Female Health Company (FHC) (NASDAQ:FHCO) reminds and urges its shareholders to vote for the proposed merger with Aspen Park Pharmaceuticals, Inc. (APP) before the upcoming special meeting of FHC shareholders, which will be held on Tuesday, September 20, 2016.  FHC’s shareholders of record as of July 28, 2016 are permitted to vote. 

FHC Shareholders – How to Vote

To ensure that your shares of FHC Common Stock are voted at the special meeting, submit your proxy OR, if your shares of FHC Common Stock are held in the name of a broker, bank or other nominee, contact your broker, bank or other nominee.  If you do not vote or do not instruct your broker, bank or other nominee how to vote, it will have the same effect as voting “AGAINST” the approval of the proposed merger.

Below are two convenient ways to vote.  FHC highly recommends shareholders vote electronically or by phone.  Please have your control number ready while voting.  The control number is located on your proxy card.

The FHC Board Recommends Shareholders Vote “FOR” all of the proposals.

FHC’s Board of Directors believes the merger is a remarkable opportunity to transform FHC into a more profitable and rapidly growing entity and urges shareholders to vote as soon as possible FOR the proposals.

The FHC Board’s rationale is straightforward.  FHC is a single product company that has enjoyed a long run as the only provider of an FDA approved female condom.  Over the last 20 years, FHC has grown, bringing the FC2 Female Condom to many countries around the world.  However, a single product company cannot thrive indefinitely.  FHC now faces a more competitive business environment - its intellectual property has not been able to prevent the introduction of several World Health Organization (WHO) approved competitive products - and ever tightening government budgets around the world.  Unfortunately, some of the countries with the greatest need for FC2 are also in desperate financial straits. 

In order to grow and increase shareholder value, FHC must diversify its opportunities by adding products to its offering.  This transaction does exactly that.  APP brings multiple near-term products with extremely large market opportunities.  The success of any one of APP’s products could dwarf sales of FC2.  APP has strategically built a portfolio that includes four potentially lower-risk / higher-return products that utilize a regulatory approval pathway, which significantly reduces the time, cost and risk in obtaining FDA approval.  As recently announced, APP’s Tamsulosin DRS, a proprietary medication for the treatment of benign prostatic hyperplasia (BPH) - a $3.5 billion market, has been cleared by the FDA for the accelerated, 505(b)(2) regulatory approval pathway.  The plan is to submit the New Drug Application (NDA) for Tamsulosin DRS in 2017 and, if approved, launch the product in early 2018.

The full meeting agenda is detailed in FHC's definitive proxy statement, which has been filed with the Securities and Exchange Commission and mailed to all FHC stockholders of record as of July 28, 2016, the record date for the special meeting of FHC's shareholders to approve matters relating to the proposed merger.

About The Female Health Company

The Female Health Company, based in Chicago, Illinois, manufactures and markets the FC2 Female Condom® (FC2). Since the Company began distributing FC2 in 2007, the product has been shipped to 144 countries. The Company owns certain worldwide rights to the FC2 Female Condom®, including patents that have been issued in a number of countries around the world. The patents cover key aspects of the FC2 manufacturing process and design.  The FC2 Female Condom® is the only currently available female-controlled product approved by FDA that offers dual protection against sexually transmitted infections, including HIV/AIDS, the Zika virus and unintended pregnancy. The World Health Organization (WHO) has cleared FC2 for purchase by U.N. agencies.

About Aspen Park Pharmaceuticals

Aspen Park Pharmaceuticals, Inc. is a privately held therapeutics company focused on the development and commercialization of pharmaceutical and consumer health products for men’s and women’s health and oncology. For men, product and product candidates are in the areas of benign prostatic hyperplasia, male infertility, amelioration of side effects of hormonal prostate cancer therapies, gout, sexual dysfunction, and prostate cancer. For women, product candidates are for advanced breast and ovarian cancers and for female sexual health. Aspen Park Pharmaceuticals is planning to launch in the United States the PREBOOST™ OTC product for treating premature ejaculation in Q4 of fiscal 2016. Aspen Park Pharmaceuticals has offices in New York City, New York.